# US 2013/0252947 A1 · BMP-2 Upregulating Compounds For Healing Bone Tissue And Screening Methods For Selecting Such Compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0252947 A1
- Document ID: US20130252947A1
- Status: Published application
- Kind: A1
- Application number: 13/896,993
- Filed: 2013-05-17
- Published: 2013-09-26
- Earliest claimed: 2011-06-08
- Assignees: Southwest Research Institute
- Applicants: Southwest Research Institute
- Inventors: Jorge Gianny ROSSINI
- Web page: https://patentgrep.com/patent/US20130252947A1

## CPC

- A61K 31/5415: ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/4402: only substituted in position 2, e.g. pheniramine, bisacodyl
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/472: Non-condensed isoquinolines, e.g. papaverine
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 38/18: Growth factors; Growth regulators
- A61K 38/22: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to a method to stimulate endogenous BMP-2 up-regulation in a subject which method comprises administering to a subject an effective amount of an H1 receptor antagonist, whereby endogenous BMP-2 up-regulation is stimulated in said subject. Also provided is a pharmaceutical formulation including an H1 receptor antagonist present in an effective amount to stimulate BMP-2 up-regulation in a subject and a kit.

## Claims

### Claim 1

A method to stimulate endogenous BMP-2 up-regulation in a subject which method comprises administering to a subject an effective amount of an H1 receptor antagonist, whereby endogenous BMP-2 up-regulation is stimulated in said subject.

### Claim 2 (depends on 1)

The method of independent claim 1, wherein said H1 receptor antagonist is one or more antagonists selected from the following: a first a first generation H1 receptor antagonist and a second generation H1 receptor antagonist.

### Claim 3 (depends on 1)

The method of independent claim 1, wherein said H1 receptor antagonist is selected from the group consisting of terfenadine, promethazine, ebastine, pheniramine, carebastine and astemizole.

### Claim 4 (depends on 1)

The method of independent claim 1, wherein said H1 receptor antagonist is terfenadine.

### Claim 5 (depends on 1)

The method of independent claim 1, wherein said H1 receptor antagonist is carebastine.

### Claim 6 (depends on 1)

The method of independent claim 1, wherein said H1 receptor antagonist is ebastine.

### Claim 7 (depends on 1)

The method of independent claim 1, wherein said H1 receptor antagonist is astemizole.

### Claim 8 (depends on 1)

The method of claim 1 wherein said subject is characterized by one or more conditions selected from the group consisting of osteoporosis, bone fractures, osteolytic lesions, metastic bone disease, segmental bone defects, post-plastic surgery that benefits from bone healing.

### Claim 9 (depends on 1)

The method of claim 1 further comprising administering to said subject one or more additional agents that promote tissue growth or infiltration.

### Claim 10 (depends on 7)

The method of claim 7, wherein said one or more additional agents is selected from the group consisting of epidermal growth factors, fibroblast growth factors, platelet-derived growth factors, transforming growth factors, parathyroid hormones, leukemia inhibitory factors, insulin-like growth factors, bone morphogenetic proteins and antiresorptive agents.

### Claim 11 (depends on 1)

The method of claim 1, wherein said subject is human.

### Claim 12 (depends on 1)

The method of claim 1, wherein said subject is a non-human vertebrate.

### Claim 13 (depends on 1)

The method of claim 1, wherein said compound is administered parenterally.

### Claim 14 (depends on 1)

The method of claim 1, wherein said compound is administered enterally.

### Claim 15 (depends on 1)

The method of claim 1, wherein said endogenous BMP-2 up-regulation enhances bone formation.

### Claim 16 (depends on 1)

The method of claim 1, wherein said endogenous BMP-2 up-regulation enhances cartilage formation.

### Claim 17

A pharmaceutical formulation for the delivery of an endogenous BMP-2 up-regulator, comprising:
an H1 receptor antagonist present in an effective amount to stimulate BMP-2 up-regulation in a subject.

### Claim 18 (depends on 17)

The pharmaceutical formulation of claim 17, further comprising a pharmaceutically acceptable vehicle in which said H1 receptor antagonist is dispersed or dissolved.

### Claim 19 (depends on 18)

The pharmaceutical formulation of claim 18, wherein said pharmaceutically acceptable vehicle is selected from the group consisting of saline, buffered saline, 5% dextrose in water, borate-buffered saline, dimethyl sulfoxide, BGJb media, and combinations thereof.

### Claim 20 (depends on 17)

The pharmaceutical formulation of claim 17, wherein said composition is in a form chosen from solution, suspension, coated capsule, suppository, lyophilized powder, transdermal patch, bone growth matrix, cartilage growth matrix, and controlled release films.

### Claim 21 (depends on 15)

The pharmaceutical formulation of claim 15, further comprising one or more of the following excipients, preservatives, solubilizers, stabilizers, buffering agents, albumin, lubricants, fillers, and stabilizers.

### Claim 22

A kit comprising:
a vessel containing a composition including from 0.02 mg/kg to 1,000 mg/kg an H1 receptor antagonist; and
instructions for the administration of said H1 receptor antagonist to a subject in need thereof in an effective amount for endogenous BMP-2 upregulation.
